In the INUSpheresis® ward of the INUS day hospital, the following basic forms of therapeutic INUSpheresis® are available:



Cell absorptions-INUSpheresis®

The INUS day hospital is internationally oriented. Therefore, it reserves the right to include also the guidelines and recommendations by other international apheresis associations (e.g. Japanese Apheresis Association, American Apheresis Society International Apheresis Association, International Society for Therapeutic Apheresis, guidelines of the U.S. Food and Drug Administration (FDA), etc.) in the diagnosis and response to the question of INUSpheresis® therapy. Overall, guidelines and recommendations by 17 international apheresis associations can be applied.



Indications for therapeutic INUSpheresis® in the INUS day hospital

(in (german) alphabetical order)


Age-related macular degeneration - dry form of disease progression


• Chronic inflammatory demyelinating polyneuropathy (CIDP)

• Ulcerative colitis failure of chemotherapy and/or impending operative bowel resection

• Diabetic foot syndrome with impending limb amputation in case of failure of conservative and conventional surgical therapy

• Dilated cardiomyopathy - beta-receptor antibody positive detection

• Eaton Lambert syndrome (tumour-associated nerve disorder)

• Disseminated encephalitis (multiple sclerosis) - failure of interleukin alpha therapy or formation of antibodies against                  therapeutic interleukin with a progressive course

• Familial heterozygous hypercholesterolaemia with failure / adverse effect of conservative therapy and/or early and                      progressive atherosclerosis / heart attack / stroke / infection of the renal vessels

• Familial homozygous hypercholesterolaemia

• Focal segmental glomerulonephritis of the own kidney or after renal transplantation with nephrotic syndrome and/or severe        hypertriglyceridemia with failure of chemotherapy / cholesterol synthesis inhibitor therapy and rapid increase in renal failure      (loss of kidney function)

• Glomerulonephritis (inflammatory kidney disease) with pathogenetic cause - failure and/or serious side effects of                        chemotherapy

• Guillain Barre syndrome - chronic / acute form of progression

• Haemophilia in case of detection of antibodies against factor V

• Acquired haemophilia (bleeding tendency) in case of factor V antibody detection

• HLA sensitivity in renal transplant

• IgM-associated polyneuropathy (tumour-associated nerve disorder)

• Isolated familial Lp(a) hyperlipoproteinaemia with premature atherosclerosis / heart attack / stroke / infection of the renal            vessels / inoperable arterial disease of the legs

• Cryoglobulinaemic vasculitis (autoimmune vascular inflammation by cryo-proteins)

• Linear IgA dermatosis

• Lupus erythematosus failure / severe side effects of chemotherapy

• Lupus erythematosus with progressive renal attack (glomerulonephritis)

• Macular degeneration (adult form of disease progression) - dry form of progression

• Behcet's disease - failure and/or serious side effects of chemotherapy

• Raynaud's disease - failure of conservative therapy

• Refsum disease (storage disease)

• Multiple sclerosis (see also disseminated encephalitis)

• Necrobiotic xanthogranuloma (with paraprotein)

• Nephrotic syndrome in inflammatory renal diseases (glomerulonephritis) with pathogenetic cause - failure and/or serious side    effects of chemotherapy

• Pemphigus foliaceus failure and/or serious side effects of chemotherapy

• Peripheral arterial disease (with pathogenetic cause) in case of failure of conventional and conservative surgical treatment          options and impending limb loss

• Polymyositis - failure and/or serious side effects of chemotherapy

• Retinitis pigmentosa in Refsum disease

• Rheumatoid arthritis - in case of failure of chemotherapy and extreme progression

• Progressive systemic scleroderma with renal attack (glomerulonephritis)

• Arndt Gottron Scleromyxoedema with renal attack and detection of paraprotein - failure and/or serious side effects of                  chemotherapy

• Stiff Man syndrome

• Thromboangiitis obliterans (Winiwarter-Buerger disease) (an alternative to amputation)

• Transplant vasculopathy after heart transplantation

• Vulgar pemphigus failure and/or serious side effects of chemotherapy

• Xanthogranuloma (necrobiotic) with paraprotein




Innovative indications for therapeutic apheresis

These indications are intended as healing and treatment trials (in the sense of last resort).


These indications are listed alphabetically in the following:


• Alzheimer's disease and dementia (pathogenesis see below)

• Aerotoxic syndrome (pathogenesis see below)

• Exposure to heavy metals, solvents and other environmental toxins that cause serious symptoms in the field of autoimmune        diseases and/or nerve diseases and/or skin conditions (e.g. aerotoxic syndrome, fibromyalgia, blistering skin diseases, toxic         nerve damage, kidney damage, MCS, CFS, ciguatera poisoning, Parkinson's and dementia syndromes)

• Borreliosis as late borreliosis with severe disease progressions which are no longer manageable by conservative treatment          (CFS / Guillain Barre syndrome resistant to immunoglobulin therapy / severe therapy-resistant autoimmune diseases, such as    rheumatism, systemic collagenosis, lupus diseases, cardiomyopathies based on detected autoantibodies against the heart in          case of borreliosis)

• Chronic fatigue syndrome (CFS)

• Chronic hepatitis C (covered by the statutory health insurance in Japan)

• Fibromyalgia syndrome

• Hypertension (high blood pressure) arterial alpha1 and/or angiotensin 1 antibody positive detection - none or only difficult          treatment by conventional pharmacotherapy

• Hyperbilirubinaemia with severe congenital metabolic disorders of the liver with the threat of brain damage

• Multiple chemical hypersensitivity syndrome (MCS)

• Multiple sclerosis (according to the study by the Canadian-American Apheresis Society)